Back to Search
Start Over
Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
- Source :
- Gastroenterologia y hepatologia. 42(5)
- Publication Year :
- 2018
-
Abstract
- The current goals of treatment in inflammatory bowel disease, both Crohn's disease and ulcerative colitis, are to achieve clinical, endoscopic and ideally histological remission and improve the quality of life of these patients. Current therapies are effective in achieving remission in most cases, but there is a lack of clear guidelines on their optimal duration. This review aims to evaluate the current evidence on the withdrawal of therapy with 5-aminosalicylates, thiopurines and methotrexate. We also aim to identify which specific group of patients, while in remission and in the absence of risk factors, may be able to discontinue therapy without a significant risk of relapse.
- Subjects :
- medicine.medical_specialty
Azathioprine
Disease
Inflammatory bowel disease
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Mesalazine
Internal medicine
Medicine
Humans
Significant risk
Mesalamine
business.industry
Mercaptopurine
Anti-Inflammatory Agents, Non-Steroidal
Remission Induction
medicine.disease
Inflammatory Bowel Diseases
Ulcerative colitis
Methotrexate
chemistry
Withholding Treatment
030220 oncology & carcinogenesis
030211 gastroenterology & hepatology
business
Immunosuppressive Agents
medicine.drug
Subjects
Details
- ISSN :
- 02105705
- Volume :
- 42
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Gastroenterologia y hepatologia
- Accession number :
- edsair.doi.dedup.....40f1cf4f912af67a91c63f34cb940d4d